Candidemia in the Intensive Care Unit
Candidemia in the Intensive Care Unit
复制标题
DOI：
10.1016/j.ccm.2017.04.010
复制
发表时间：
2017-09-01
影响因子：
5.7
通讯作者：
Chasan, Rachel
中科院分区：
文献类型：
--
作者：
Epelbaum, Oleg;Chasan, Rachel
糖尿病对重症监护室（ICU）社区提出了几项挑战。这种感染的识别和治疗经常被延迟，在血培养中检测到念珠菌之前，通常会出现严重的临床恶化和死亡。确定个别患者的最高风险发展为念珠菌血症仍然是一个不完善的科学;抗真菌治疗的作用前培养诊断尚未完全确定在ICU。由于缺乏成熟的分子技术来早期检测念珠菌血症，阻碍了减少这种感染的严重临床和经济影响的努力。棘白菌素是治疗ICU念珠菌血症的推荐抗真菌药物类别。
Candidemia presents several challenge's to the intensive care unit (ICU) community. Recognition and treatment of this infection is frequently delayed, with dramatic clinical deterioration and death often preceding the detection of Candida in blood cultures. Identification of individual patients at the highest risk for developing candidemia remains an imperfect science; the role of antifungal therapy before culture diagnosis is yet to be fully defined in the ICU. The absence of well-established molecular techniques for early detection of candidemia hinders efforts to reduce the heavy clinical and economic impact of this infection. Echinocandins are the recommended antifungal drug class for the treatment of ICU candidemia.